DocWire News Editors

DocwireNews

Chicago&mdash;Clinical decisions as well as drug development for prostate cancer are facilitated with intermediate clinical end points. The international intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) working group reported that metastasis-free survival is a strong surrogate of overall survival in hormone-sensitive localized prostate cancer. Matthew Raymond Smith, MD, and colleagues conducted a study to examine the relationship between metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).Results of the analysis were reported during a poster session at the ASCO 2018 Annual Meeting in a poster titled Association of Metastasis-Free Survival (MFS) and Overall Survival (OS) in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC).The researchers utilized data from the phase 3 SPARTAN trial in men with high-risk nmCRPC. Following adjustments for covariates, a Cox proportional hazard regression model was used to evaluate the relationship of overall survival and the development of metastases. Spearman&rsquo;s and Fleisher&rsquo;s correlation statistics were used to assess the correlation of metastasis-free survival and overall survival.Median time to metastasis among 1207 patients with nmCRPC as of May 2017 was 40.5 months. Compared with patients without metastasis, those who developed metastasis at 6, 9, and 12 months had significantly shorter median overall survival. Following adjustment for baseline covariates, the association between the development of metastases and overall survival remained.There was a significant positive correlation between metastasis-free survival and overall survival (Spearman&rsquo;s correlation coefficient, 0.62; P&lt;.0001). The parametric Fleisher&rsquo;s statistical model confirmed the positive correlation (correlation coefficient, 0.69), with ~50% of variability in overall survival explained by metastasis-free survival.In conclusion, the researchers said, &ldquo;Metastasis-free survival has a significant association with overall survival and is predictive of overall survival in high-risk nmCRPC. This analysis demonstrates that metastasis-free survival is a meaningful and valid intermediate clinical end point for overall survival.&rdquo;Clinical trial information: NCT01946204Source: Smith MR, Mehra M, Nair S, Lawson J, Small EJ. Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC). Abstract of a poster presented at the American Society of Clinical Oncology 2018 Annual Meeting, June 2, 2018, Chicago, Illinois.&nbsp;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Metastasis-Free Survival Predictive of Overall Survival in nmCRPC

ASCO 2018

Chicago—Clinical decisions as well as drug development for prostate cancer are facilitated with intermediate clinical end points. The international intermediate Clinical ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe